We have located links that may give you full text access.
Children with differentiated thyroid cancer achieve adequate hyperthyrotropinemia within 14 days of levothyroxine withdrawal.
Journal of Clinical Endocrinology and Metabolism 2005 November
CONTEXT: The preparation for radioiodine administration recommended by the current pediatric literature is a 6-wk withdrawal that typically includes the transient administration of T3. Compared with adults, T4 clearance rates and serum TSH to free T4 ratios are higher in children, implying that pediatric patients can achieve adequate hyperthyrotropinemia with shorter levothyroxine withdrawals.
OBJECTIVE: The objective of this study was to determine whether children with differentiated thyroid cancer achieve adequate hyperthyrotropinemia using an abbreviated levothyroxine withdrawal protocol.
DESIGN: The study design was a retrospective analysis of 15 consecutive levothyroxine withdrawals performed without T3 at Children's Hospital Boston.
PATIENTS: Eleven children with differentiated thyroid cancer were included. The average age at the time of withdrawal was 12.5 +/- 0.8 yr.
MAIN OUTCOME MEASUREMENT: Serum TSH concentrations obtained after the discontinuation of levothyroxine were analyzed to determine the time interval required to achieve a serum TSH level greater than 25 microU/ml for each patient.
RESULTS: Adequate hyperthyrotropinemia was documented in all children tested by d 14. The mean interval required to achieve a serum TSH level above 25 microU/ml from a suppressed serum TSH was 12.3 +/- 0.7 d.
CONCLUSIONS: Shorter withdrawals minimize hypothyroid morbidity and the theoretical risk of decreased 131micro)I residence time from excessive hyperthyrotropinemia. These benefits are amplified in children due to their high incidence of distant metastases. We propose an abbreviated 2-wk withdrawal protocol to facilitate the adjunctive therapy and surveillance of children with follicular cell-derived cancers.
OBJECTIVE: The objective of this study was to determine whether children with differentiated thyroid cancer achieve adequate hyperthyrotropinemia using an abbreviated levothyroxine withdrawal protocol.
DESIGN: The study design was a retrospective analysis of 15 consecutive levothyroxine withdrawals performed without T3 at Children's Hospital Boston.
PATIENTS: Eleven children with differentiated thyroid cancer were included. The average age at the time of withdrawal was 12.5 +/- 0.8 yr.
MAIN OUTCOME MEASUREMENT: Serum TSH concentrations obtained after the discontinuation of levothyroxine were analyzed to determine the time interval required to achieve a serum TSH level greater than 25 microU/ml for each patient.
RESULTS: Adequate hyperthyrotropinemia was documented in all children tested by d 14. The mean interval required to achieve a serum TSH level above 25 microU/ml from a suppressed serum TSH was 12.3 +/- 0.7 d.
CONCLUSIONS: Shorter withdrawals minimize hypothyroid morbidity and the theoretical risk of decreased 131micro)I residence time from excessive hyperthyrotropinemia. These benefits are amplified in children due to their high incidence of distant metastases. We propose an abbreviated 2-wk withdrawal protocol to facilitate the adjunctive therapy and surveillance of children with follicular cell-derived cancers.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app